AstraZeneca said on Thursday its drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening.
The late-stage study, dubbed “CALLA,” tested progression-free survival of patients with the combination against chemoradiotherapy alone, the drugmaker said, and the results are seen as a setback for its efforts in a major area of focus.
